Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Leech

Nurse Practitioner, Women's Health Lawrenceville, GA Nurse Practitioner

NPI 1104964006 CMS profile 10624397

771 Old Norcross Rd, Lawrenceville, GA 30046

Open in the dashboard

General payments

$2,483

82 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Leech of Lawrenceville, GA is reported in the CMS Open Payments database as having received $2,483 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $860 34
2024 General $441 11
2023 General $646 21
2022 General $314 10
2021 General $222 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Leech
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Jennifer Leech were reported at $860. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Jennifer Leech Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $222 $110 $33–$291 $132
2022 $314 $122 $40–$314 $149
2023 $646 $131 $40–$333 $160
2024 $441 $123 $43–$298 $164
2025 $860 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $577 14 payments
  2. Merck Sharp & Dohme Corporation $336 14 payments
  3. GlaxoSmithKline, LLC. $307 8 payments
  4. Pfizer Inc. $200 10 payments
  5. ImmunoGen, Inc. $179 4 payments
  6. AbbVie, Inc. $167 5 payments
  7. Caris MPI, Inc. $157 3 payments
  8. Astellas Pharma US Inc $111 4 payments
  9. Myriad Genetic Laboratories, Inc. $106 4 payments
  10. Seattle Genetics, Inc. $51 2 payments
  11. Other $290 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,393 81 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. LYNPARZA Oncology $456 12 payments
  2. TIVDAK $251 12 payments
  3. KEYTRUDA $250 11 payments
  4. LYNPARZA Oncology $205 10 payments
  5. Elahere Oncology $179 4 payments
  6. ZEJULA Oncology $172 3 payments
  7. ELAHERE Oncology $167 5 payments
  8. MI CANCER SEEK $157 3 payments
  9. JEMPERLI $135 5 payments
  10. ZEJULA Oncology $135 5 payments
  11. Other $675 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

78

Median for Nurse Practitioner: 389

Drug cost

$1,498

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 11 $1,015
Duloxetine Hcl Generic 13 $161
Gabapentin Generic 14 $158
Ondansetron Hcl Generic 18 $123
Levothyroxine Sodium Generic 11 $35
Metoprolol Tartrate Generic 11 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$13,090

Medicare's payments for the services billed

Medicare patients

133

Average age 72

Services billed

260

133 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Cancer 56%
Arthritis 41%
Chronic kidney disease 28%
Diabetes 25%
Osteoporosis 20%
Depression 18%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $206
  • Merck Sharp & Dohme Corporation $27
$232 — —
ELAHERE
  • AbbVie, Inc. $72
$72 — —
TIVDAK
  • PFIZER INC. $54
$54 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $35
$35 — —
JEMPERLI
  • GlaxoSmithKline, LLC. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record